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Purpose: To test the hypothesis that adjunctive slow release dexamethasone implant (Ozurdex ®) 
can improve the outcomes of vitreoretinal surgery for established PVR   
Design: A two year, single-center prospective, participant and surgeon-masked randomized-
controlled-clinical trial (EudraCT No 2011-004498-96). 
Subjects: One hundred and forty patients requiring vitrectomy surgery with silicone oil for retinal 
detachment with established PVR (Grade C) were randomized to either standard (control) or study 
treatment (adjunct) in a 1:1 allocation ratio. 
Methods: Intraoperatively, the adjunct group received an injection of 0.7mg of slow release 
dexamethasone (Ozurdex) at the time of (a) vitrectomy surgery and (b) at silicone oil removal.  The 
control group received standard care. 
Outcome Measures: Primary outcome measure was the proportion of patients with a stable retinal 
reattachment with removal of silicone oil without additional vitreoretinal surgical intervention at 6 
months.  Secondary outcomes included i) final visual acuity (median and ETDRS of 55 letters or 
better), ii) cystoid macular edema (CMO), foveal thickness and macular volume iii) development of 
overt PVR recurrence, iv) complete and posterior retinal reattachment, vi) tractional retinal 
detachment, vii) hypotony/raised IOP, viii) macula pucker/epiretinal membrane, ix) cataract, x) 
quality of life 
Results: All 140 patients were recruited within 25 months of study commencement; 138 patients 
had primary outcome data.  Primary outcome assessment showed similar results in anatomical 
success between the two groups (49.3% vs 46.3%, adjunct vs control, (Odds Ratio 0.89, 95% 
Confidence interval 0.46 – 1.74, p= 0.733).  Mean visual acuity at 6 months was 38.3 ETDRS letters 
and 40.2 letters in the adjunct and control group respectively. Secondary anatomical outcomes 
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(complete/posterior reattachment rates and PVR recurrence) were comparable between the two 
groups.  At 6 months, fewer adjunct patients had CMO (42.7%) or a foveal thickness of >300µm 
(47.6%) compared to controls (67.2% and 67.7%, respectively p= 0.004,p= 0.023). 
Conclusion:  A slow-release dexamethasone implant does not improve the primary anatomical 
success rate in eyes undergoing vitrectomy surgery with silicone oil for PVR. Further clinical trials 
are indicated to improve anatomical and visual outcomes in these eyes, but this study suggests 
that there is a greater reduction in CMO observed at six months in vitrectomised eyes treated with 




















Proliferative vitreoretinopathy (PVR) is the most common cause of late anatomic failure following 
vitrectomy for rhegmatogenous retinal detachment. Its reported incidence ranges from 5-11% of all 
rhegmatogenous retinal detachments1.  PVR can be considered a maladapted wound healing retinal 
response in which cellular proliferation, migration and deposition results in the formation of 
fibrocellular membranes on both surfaces of the retina and the posterior hyaloid face 1. Contraction 
of these membranes can result in distortion of normal retinal topography with visually detrimental 
sequelae, and/or tractional retinal detachment, with the reopening of pre-existing breaks or the 
formation of new ones.  
PVR is a challenging vitreoretinal surgical problem and despite improvements in instrumentation 
and technique, a significant number of cases fail to achieve reattachment. Multiple procedures are 
frequently required to eventually achieve final retinal attachment with poor visual results and 
unsatisfactory binocular visual outcomes 1-3. Furthermore,  PVR management is costly in patient time 
and healthcare resources 3. Numerous adjunctive medications have been previously evaluated in 
clinical trials 4-12, yet no effective and safe adjunct has gained widespread acceptance.  
Experimentally, corticosteroids can potentially influence both the inflammatory and proliferative 
components of the PVR process via a variety of modes of administration 13, 14 15 without evidence of 
demonstrable retinal toxicity 16.  
Clinically, intravitreal crystalline cortisone was first reported in 2000 by Jonas et al to be well 
tolerated in PVR cases undergoing vitrectomy. 17 Previous small scale, uncontrolled clinical studies 
of PVR have suggested that systemic prednisolone 18, infused dexamethasone 19 and intravitreal 
triamcinolone 20, 21 may reduce the severity of PVR although none of these studies were of sufficient 
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power to provide a definitive answer.  A slow-release preparation of corticosteroid may offer 
additional advantages over other agents, through sustained activity during the active phase of the 
PVR process.  
 
The aim of this study was to determine whether a 0.7mg slow-release preparation of 
dexamethasone given at the time of vitrectomy surgery and repeated at the time of oil removal,  
could improve  anatomical and visual outcomes in eyes with PVR.  
 
 
Patients and Methods 
This phase IIIb, single-centre, participant-masked, prospective randomised controlled clinical trial 
was performed at Moorfields Eye Hospital NHS Foundation Trust between February 2012 and 
February 2015 22. Prior to participant recruitment, Moorfields Research Management Committee 
approval was obtained, a favourable opinion from the National Research and Ethics Service 
Committee London - Central was received (11/LO/1685) and the study was granted a clinical trials 
authorisation by the MHRA. The trial was registered on the European Clinical Trials Database 
(EudraCT No 2011-004498-96). The study was conducted in accordance with the International 
Conference on Harmonisation for Good Clinical Practice, as set out in the European Union Clinical 
Trials Directive (2001) and associated UK Regulations (2004). The study complied at all times with 
the Declaration of Helsinki (2000). Patients provided written informed consent before entering the 
trial. An independent Data Monitoring Committee (DMC) and Trial Steering Committee (TSC) 






The study population consisted of male and female patients aged 18 years and over. Eligible patients 
were those undergoing pars plana vitrectomy with silicone oil tamponade for rhegmatogenous 
retinal detachment with established (Grade C) PVR 23.  
The exclusion criteria were as follows: a) open globe injury b) a diagnosis of ocular hypertension on 
2 or more pressure lowering medications or a definite diagnosis of glaucoma (if in the opinion of a 
glaucoma specialist, the patient is at high risk of visual damage from raised IOP) c) uncontrolled 
uveitis, d) previous steroid induced glaucoma,  e) proliferative diabetic retinopathy or 
vasculopathy, f) pregnant or breastfeeding females, g) previous known adverse reaction to the 
Ozurdex®, h) suspected ocular/periocular infection (e.g Herpes Simples Virus, Varicella Zoster 
Virus, mycobacterial, fungal disease, i) aphakia or patients in whom a lensectomy is planned at 
time of surgery, j) pre-existing anterior chamber intraocular lens. 
There were no restrictions on the number of previous vitreoretinal procedures.  
 
Randomisation 
A randomization schedule of 140 treatment allocations against 140 study IDs was produced by a 
statistician using random permuted blocks of varying sizes.  The randomisation schedule was 
provided to the clinical trials pharmacy at the study site, who prepared treatment packs according to 
the randomisation schedule.  Upon confirmation of eligibility, participants were allocated to the 
lowest unused study number. Out of hours (i.e weekends and bank holidays), the next study number 
in sequence was kept in a sealed treatment pack in a secure location on site when access to the trials 
pharmacist was limited. 70 patients were randomised to receive standard surgical care (Control 
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Group) and 70 patients were randomised to receive standard surgical care in addition to the 
supplementary adjunctive dexamethasone implant (Adjunct Group).    
 
Intervention 
Both groups received the standard vitreoretinal operative procedure which their ocular condition 
required. Consultants or senior fellows (2nd year fellowship) performed the operative procedures.  
ADJUNCT GROUP 
Upon confirmation of successful retinal reattachment and completion of silicone oil exchange, the 
operating surgeon was asked to clinically grade the level of PVR using the standardized 
classification system in current practice 23. Thereafter, the surgeon was asked to inject a 0.7mg 
slow release dexamethasone implant through the final open sclerotomy port prior to suturing.  
A similar procedure was followed for the second implant administration at the time of oil removal. 
Upon confirmation that the retina remained attached following removal of oil, the surgeon was 
again asked to confirm the retinal status and the presence or absence of PVR. As a variety of 
techniques were used to remove silicone oil, particularly if combined cataract surgery was 
performed, the implant was either injected through a sclerotomy port (if used) or via the 
conventional method of delivery 24.   
CONTROL GROUP 
Following successful retinal reattachment, completion of silicone oil exchange and grading the 
level of PVR , the surgeon was informed that no adjunctive medication was required and the final 





Participants were masked to their treatment allocation for their entire duration of the trial, and 
preservation of masking status was confirmed upon exit. Additionally, the operating surgeon was 
masked until the end of the surgical procedure, to avoid any bias in surgical management. The 
treatment allocation was revealed to the operating surgeon in a manner by which the patient 
remained masked. It was not possible to mask the investigators at follow up, as the primary IMP 
was sometimes visible on posterior chamber assessment.  
 
Assessments and Schedule 
Postoperative study visits mirrored the routine schedule for vitreoretinal procedures at the study 
site and were conducted in the NIHR Clinical Research Facility at Moorfields Eye Hospital (PB, DC 
or MZ); day 1, day 10, 4-6 weeks, 3 months, 6 months, 9 months and 12 months. At each 
scheduled postoperative study visit, a full ophthalmic assessment was completed to include slit 
lamp biomicroscopy (+/- indirect binocular ophthalmoscopy when required) to assess retinal 
attachment status  and PVR grade 23 and parameters including best corrected visual acuity (ETDRS 
chart )  applanation tonometry and anterior segment assessment  were recorded. Spectral domain 
optical coherence tomography (SD-OCT) (Heidelberg) was used to determine the presence or 
absence of cystoid macular edema, epiretinal membrane and persistent submacular fluid. Central 
foveal thickness and macular volume were determined using automated algorithms incorporated 
into the Heidelberg software.  
Two additional study visits at Days 60 post implant injection were performed to measure the IOP. 
Management of postoperative elevated IOP followed an algorithm previously approved by an 
independent glaucoma specialist who was a member of the external DMC 22.   
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Any additional vitreoretinal surgical interventions over the trial period were considered 
reoperations and recorded as such. Indirect laser retinopexy was performed at the discretion of 
the patient’s vitreoretinal consultant and was not considered a reoperation  
Adverse Events (AE)  
Adverse events were recorded and reported to the sponsor as per the study protocol 22.  Study-
specific definitions for elevated IOP (>25mmHg) were adhered to. Furthermore, as cataract is an 
inevitable consequence of vitrectomy surgery, it was only considered an AE if in the treating 
clinician’s opinion, it had progressed at a rate requiring expedited surgical extraction prior to the 
planned removal of silicone oil.  
 
Primary outcome 
The primary outcome measure was the proportion of patients with a stable retinal reattachment 
with removal of silicone oil without additional vitreoretinal surgical intervention at 6 months post 
study vitrectomy. 
Secondary outcomes 
 Secondary outcomes at 6 and 12 months post primary study vitrectomy surgery were as follows:  
i) visual acuity (a comparison of the mean/median visual acuity and the proportion of 
patients in each group achieving a VA of 55 ETDRS letters or better) 
ii) macula edema and thickness (OCT analysis) i.e the proportion of patients in each 
group with a central A1 macula subfield measure of >300um   
iii) the proportion of patients in each group who develop overt PVR recurrence 
iv) the proportion of patients in each group achieving complete retinal reattachment  
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v) the proportion of patients in each group achieving stable posterior (post 
equatorial) retinal reattachment  
vi) the proportion of patients in each group with a tractional retinal detachment  
vii) the proportion of patients in each group who suffer hypotony (defined as IOP 
<6mmHg and/or raised IOP (defined as >25mmHg) at any timepoint during the 
study period 
viii) the proportion  of patients in each group who develop the presence of macula 
pucker/epiretinal membrane and/or require macula ERM surgery at any time point 
during the study 
ix) the proportion of patients in each group who require cataract surgery at any time 
point during the study 
x) Quality of Life assessment – a comparison in the median/mean  scores of both 
SF36 and VFQ between both groups 
 
Sample size 
Based on the results of the primary outcome measure from a trial of the same patient group 
carried out in the study centre 7 , 66 patients per study arm are required for a study power of 
85% to detect, at the 5% level, a 50% improvement in success of the adjunctive regime 
(reducing failure from 49% to 24%).  This reduction in failure rate was deemed clinically 
meaningful. Allowing for a 5% loss to follow up rate (observed in previous studies at the study 






Baseline characteristics for each group were presented as mean and standard deviation (SD) for 
continuous (approximately) normally distributed variables, medians and interquartile ranges 
(IQR) for non-normally distributed variables, and frequencies and percentages for categorical 
variables. 
Analysis was conducted following the intention to treat (ITT) principle. An available case analysis 
was conducted together with best/worst case scenario imputation analysis and results 
compared in a sensitivity analysis. For the primary outcome, reasons for missingness were 
examined using logistic regression of covariates on an indicator of missingness. 
All statistical tests used a 2-sided p-value of 0.05. All confidence intervals presented were 95% 
and two-sided. 
The primary outcome was reported by treatment group with 95% confidence intervals (CI) 
computed by the exact binomial method. Treatment effect estimate was computed as an odds 
ratio (OR) and respective 95% CI using univariate logistic regression. 
Treatment effect estimates with 95%CIs were also computed by PVR severity (severe i.e. CA or 
CP > 4 versus less severe i.e. CA and CP ≤ 4). 
Summary statistics for all secondary outcomes were computed by treatment group at 6 and 12 
months after initial surgery (12 months data to be disseminated separately). Analysis of 
covariance was used to explore difference between treatment arms in change from baseline in 
continuous variables (e.g. visual acuity, quality of life). 
Sensitivity analysis was conducted using analysis of covariance to explore difference between 
treatment arms in change from baseline in visual acuity at 6 and 12 months for the subgroup of 
patients with no prior reason for poor visual outcome (12 months data to be disseminated 
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separately) – this subgroup of patients was identified by the clinician (PJB) masked to treatment 
allocation and outcome. 
The proportion of patients who experience an AE or SAE was reported by event type and 
treatment group. 
A post-hoc exploratory analysis was conducted on patients with available quantitative SD-OCT 
readings at 6 months, using chi-squared tests to compare the proportion of patients with CMO by 





Figure 1 displays the Consort flow diagram. Patient recruitment opened in February 2012. One 
hundred and ninety two patients were assessed for eligibility of which 29 were ineligible and 
excluded. Of the remaining 163 eligible patients, 20 patients declined to participate in the study. 
Three further patients enrolled in the study but were not randomized as silicone oil was not used. 
The remaining one hundred and forty eligible patients elected to participate in the trial and were 
recruited within 24.5 months of the study commencing. The study closed at the final visit of the 
final patient in February 2015 within the original projected timeframe.  
 
Baseline Characteristics 
Baseline demographic and non-ocular characteristics are summarized in table 1 showing 
comparable gender, mean age, and ethnicity, with a Caucasian sexagenarian male preponderance 
in both groups. Ocular and retinal baseline characteristics are displayed in tables 2a, 2b and 3.  
The median refractive status in both groups was emmetropia. Approximately one third of eyes in 
each group (n=22 vs n=20, adjunct vs control, respectively) had not undergone previous 
vitreoretinal surgery, with the majority of the remaining two thirds of patients having suffered 
failed vitrectomy surgery with gas tamponade. Four patients in both groups had previously 
undergone failed scleral buckling procedures. Twice as many patients in the adjunct group (n=20) 
were noted to have ocular co-morbidity compared to the control group (n=10). These included a 
history of amblyopia, age-related macular degenerative disease and closed globe ocular trauma.  
The median presenting visual acuity was zero ETDRS letters (i.e ≤ Counting Fingers) in both groups, 
and mean intra-ocular pressure readings were 11.9mmHg and 13.3mmHg in the adjunct and 
control group, respectively. Baseline markers of inflammation and blood ocular barrier breakdown 
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(anterior chamber cells, vitreous haemorrhage and RPE cells) were comparable between the two 
groups.  
Thirty seven (52.9%) of the adjunct group patients were pseudophakic compared to thirty four 
(48.6%) control patients. Of the remainder, the majority showed signs of lens opacity with 
approximately ten percent of patients in each group with no cataract.  
The fovea was detached in 60 of 70 eyes (85.7%) in the adjunct group and in 57 eyes (81.4%) in 
the control group. The median duration of retinal detachment was 25 and 21 days in the adjunct 
and control group, respectively. The median extent of retinal detachment was comparable, with 
eight clock hours of RD recorded in the adjunct group and nine in the control arm. The median 
grades of anterior and posterior PVR (as assessed intraoperatively) were comparable between the 
two groups.  
Operative Techniques 
Table 4 outlines the operative techniques employed during the primary study vitrectomy. 38 
(54.3%) adjunct patients and 39 (55.7%) control patients underwent a retinectomy at the time of 
their primary study vitrectomy. 
 
Primary Outcome Measure 
Primary outcome data was available for 69 out of 70 patients in each group.   One patient in the 
control group was lost to follow up after month 3 and one patient in the adjunct group was 
prematurely withdrawn as they had failed primary surgery and no month 6 data was collected. It 
was subsequently agreed by both the TSC and DMC that this adjunct patient should remain in the 
study, and month 12 data was collected.   
 15 
 
There was no observed difference in primary outcome between the two groups (Table 5): 49% of 
patients (n= 34 of 69) in the adjunct group achieved a stable retinal reattachment with silicone oil 
removal without additional vitreoretinal surgical intervention at 6 months, compared to 46% 
(n=32 of 69) in the control group. (Odds Ratio (OR) 0.89, 95% Confidence interval 0.46 – 1.74, p= 
0.733 Chi Squared). Best case and worst case imputation analysis did not affect the primary 
outcome findings. Sub-group analysis stratifying by severity of PVR (Grade CP or CA > 4) did not 
show any statistically significant difference in primary outcome achievement.  
 
Secondary Outcome Measures 
Secondary outcome measures were assessed at 6 and 12 months post study vitrectomy. Six month 
outcome measures are included in this report (tables 6 to 8) and are reported on 138 of 140 patients 
unless otherwise stated in the table. Twelve month secondary outcome measures will be described 
in subsequent reports.   
 
Visual Acuity (Table 6) 
 
At six months following study vitrectomy, mean visual acuity was comparable between the two 
treatments: 38.3 ETDRS letters (standard deviation 23.7) in the adjunct group compared to 40.2 
letters (standard deviation 21.1) in the control group. A sensitivity analysis excluding eyes with 
pre-existing ocular co-morbidity limiting visual outcome was performed and did not affect the 
findings. The proportion of eyes achieving a visual acuity ≥ 55 ETDRS letters was also comparable, 
with 21 of 69 eyes (30%) in the adjunct group achieving this vision or better, compared to 17 of 69 




Secondary Anatomical Outcomes (Table 7)  
At 6 months, the proportion of patients achieving complete retinal reattachment or a stable 
posterior retinal reattachment was comparable between the two treatment groups. Similarly, the 
proportion of patients with a tractional retinal detachment at 6 months was also comparable. The 
rate of overt PVR recurrence (defined as the presence of postoperative PVR at any timepoint up to 
6 months post study vitrectomy) was 57.0% (n= 40) in the adjunct group and 59% (n=41) in the 
control group.  
There was no observed difference in the number of operations to achieve primary success (as 
defined in the primary outcome measure), however, 11 patients (16%) underwent more than one 
operation to achieve success in the control group compared to 3 patients (4.4%) in the adjunct 
group.  
 
Macular Findings (Table 8) 
At six months, for patients with available quantitative SD-OCT readings, median foveal thickness 
and macular volume were lower in the adjunct group (297µm and 8.85mm3) compared to the 
control group (365µm and 9.23 mm3). Similarly, the proportion of eyes with a foveal thickness 
>300µm in the A1 macular subfield was lower in the adjunct group (n=30, 47.6 %) compared to the 
control group (n=42, 67.7%) (OR = 2.3, 95% CI 1.12 – 4.78, p= 0.023), Chi Squared). Furthermore 
the proportion of eyes with macular oedema in the adjunct group was 42.7% (n=29) compared to 
67.2% (n=45), (OR = 2.8, 95% CI 1.37 – 5.54, p= 0.004, Chi Squared).  
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40 patients (57.1%) in the adjunct group and 41 patients (58.6%) in the control group developed 
macular ERM at any timepoint up to 6 months, with comparable rates of macular pucker surgery 
between the two groups.  
 
Cataract and IOP Outcomes 
The proportion of phakic patients in the adjunct group who underwent cataract surgery in the six 
months after the study intervention was 75.8% (n=25 of 33), compared to the 86.1% in the control 
group (n=31 of 36).  At 6 months, 84.1% of adjunct patients (n=58) were pseudophakic compared 
to 87% of control patients (n=60).  
Rates of hypotony were also similar between the two groups, with 20% of patients (n=14) in the 
adjunct group suffering at least one episode of hypotony and 24.3% (n=17) in the control group. 
The median and interquartile range IOP per time point by treatment group is displayed in the 
boxplot in Figure 2.  More patients in the adjunct group (n=32, 45.7%) experienced at least one 
episode of elevated IOP compared to the control group (n=22, 31.4%).  
 
Quality of Life Parameters 
Mean SF6 and VFQ-25 scores and mean change from baseline showed no evidence of a difference 
between the two treatment groups (supplementary Table 3).  
 
Adverse Events (AE) and Serious Adverse Events (SAE)  
There were no serious adverse reactions observed in either group. AEs are displayed in 
supplementary table 1 (online supplementary file) and totalled 595 episodes, with 285 events in 
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the adjunct group compared to 310 in the control group. 66 of 70 (94.3%) adjunct patients 
suffered at least one AE compared to 63 of 70 (90.0%) of control patients.   
The most common AE was elevated IOP. In the adjunct group there were 85 episodes (39.2%) of 
raised IOP compared to 75 (31.4%) in the control group. There were 17 serious adverse events 
during the study (16 non-ocular and one ocular), which were comparably distributed between the 
two groups (supplementary table 2). The ocular SAE was a corneal suture related abscess 
necessitating a hospital admission at the patient’s local hospital. This was deemed unrelated to 
the IMP and recorded as such.  
There were more cases of postoperative uveitis in the control group (n=24) in comparison to the 
adjunct group (n=10).  
 
Discussion 
Dexamethasone has a potency which is five times greater than triamcinolone 26 , and being more 
hydrophilic, allows for higher vitreous concentrations 27.  However, its clinical utility had previously 
been limited by its short half-life 28 and therefore necessitated the development of a slow release 
drug delivery system.  
The slow-release dexamethasone preparation (Ozurdex®), is a 6mm implant containing 700µg of 
dexamethasone in a biodegradable polymer (Novadur™, Allergan, Irvine, CA, USA).  It exhibits a 
dual-phase response of initially high concentrations of dexamethasone in the first two months, 
followed by a period of lower concentrations sustained for up to 6 months post-injection29.  In 
experimental studies, its pharmacokinetic profile was unaffected in vitrectomized eyes 30.  In 2011, 
it was first licensed for use in the treatment of macular edema secondary to retinal vein occlusion 
31 and non-infectious posterior uveitis 32. Its market authorisation was subsequently expanded in 
2014 to include patients with diabetic macular edema 33.  
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This is the first randomised controlled clinical trial (RCT) investigating the use of a slow-release 
preparation of corticosteroid in proliferative vitreoretinopathy. Recruitment was completed within 
the projected timescale and study retention rate was favourable at 98.6%.  To date there have 
been eight RCTs 4, 6-8, 10, 34-36 investigating a variety of pharmacological adjuncts targeting varying 
components of the PVR process. As yet, no single agent or combination has gained widespread 
acceptance.  
 
We found no difference in the proportion of patients achieving stable retinal reattachment with 
silicone oil removal without additional vitreoretinal surgical intervention at 6 months. 
Approximately one half of patients achieved primary success in both groups (49.3% vs 43.3%, 
adjunct vs control), which is similar to previously published rates in RCTs adopting a comparable 
primary outcome measure 7, 36.  In a study comparing the effect of 4mg of intravitreal 
triamcinolone, Ahmadieh et al 34 published an overall primary success rate of 81.3% in eyes with 
Grade C PVR undergoing vitrectomy surgery with an encircling scleral buckle. They observed no 
difference in primary or secondary outcomes between the adjunct and control arms.  
 
If we consider secondary outcomes indicative of the effect of the IMP on the PVR process, we 
found only limited evidence of differences between the two groups. A comparable proportion of 
patients achieved complete or posterior retinal reattachment and the proportion of eyes with a 
tractional RD or macular pucker was also similar between the two study groups. Furthermore, 
rates of overt PVR recurrence were similar across both groups (57% vs 59.4%, adjunct vs control). 
We did note that fewer patients in the adjunct group (n=3) required two or more operations to 
achieve attachment compared to the control group (n=11). However, as this was not investigated 
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as a secondary outcome and numbers are small, we did not test for statistical significance, and 
caution must therefore be advised when interpreting this finding.  
 
Despite finding no difference between retinal reattachment rates and PVR recurrence, statistically 
significantly fewer patients with quantitative SD-OCT readings were noted to have cystoid macular 
oedema at 6 months in the adjunct group (42.7%, n=29) compared to 67.2% (n=45) in the control 
group. Similarly the proportion of eyes with a central foveal thickness of > 300µm in the A1 
subfield was statistically significantly lower in the adjunct group (47.6%) in comparison to controls 
(67.7%). These statistical comparisons were conducted in a post hoc analysis and thus must be 
reported as exploratory.   Although CMO and foveal thickness are related variables, additional 
factors such as ERM may also affect foveal thickness.  Our findings are consistent with previous 
reports that a slow-release dexamethasone implant may be an effective treatment for CMO in 
vitrectomised eyes.  Boyer et al 37 reported a statistically significant reduction in diabetic macular 
oedema with corresponding visual improvement up to six months post implant injection in fifty-
five vitrectomised eyes. Furthermore, other authors have reported that the same slow-release 
preparation has successfully treated refractory macular oedema secondary to uveitis, venous 
occlusions, and following vitrectomy for retained lens fragments 38-40.  
 
Despite observing a difference in rates of postoperative CMO, we did not observe any difference 
in visual acuity (VA) at six months. The mean VA in the adjunct group was 38.3 ETDRS letters 
(standard deviation 23.7) compared to 40.2 letters (standard deviation 21.1) in the control group. 
This equates to LogMAR VAs of 0.96 and 0.90, and approximates to a Snellen VA of 20/160.  
Similarly, the proportion of eyes achieving a visual acuity ≥ 55 ETDRS letters (> 20/80) was also 
comparable (30.4% vs 24.6%, adjunct vs control). Mean final postoperative visual acuity in eyes 
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with PVR is notably poor and reported levels range from 2.69 LogMAR (Light Perception) 36 to 1.4 
LogMAR 7, 34. Our visual outcomes compare favourably to previous reports, however, a study 
investigating poor visual outcomes (< 20/40) after successful RD repair for PVR in thirty five 
patients, reported a 66% incidence of CMO 41. Given the lower incidence of macular edema 
observed in the adjunct group, one might have expected a correspondingly better visual outcome, 
especially when excluding eyes with limited visual potential. This observation is potentially 
important suggesting that retinal pathology other than macular edema such as neural retinal 
remodelling 42 may be the primary cause of the poor visual outcomes seen in PVR.  Further studies 
are required to identify the cause of visual loss following RD surgery in eyes with PVR. SD-OCT 
imaging of eyes following fovea-involving RDs (without PVR) have correlated outer retinal 
abnormalities with poorer visual outcomes 43-46, and thus may serve as a target for investigation in 
future studies.  
Overall, we observed a higher number of adverse events in the control group. There were fewer 
cases of postoperative uveitis in the adjunct group, perhaps indicative of the additional anti-
inflammatory activity of the dexamethasone.  
There were more episodes and a greater proportion of patients experienced at least one episode 
of elevated IOP in the adjunct group but development of glaucoma (confirmed by a glaucoma 
subspecialist) was similar between the two groups.  Our study has limitations which must be 
acknowledged.  It was not possible to mask the investigators, as the IMP was sometimes visible on 
posterior chamber assessment. However, efforts were made to minimise investigator bias, by 
masking the operating surgeon until the end of the operative procedure, and by adhering to explicit 
management protocols (e.g elevated IOP). Furthermore, some outcome assessments were objective 
through automation (SD-OCT foveal thickness and volume) and the binary nature of the primary 
outcome is less susceptible to bias. Additionally, given the heterogenous nature of the cohort, we 
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accept the limitations of detecting small differences between the two groups. Nevertheless, the 
study was designed to be pragmatic and as inclusive as possible, so as to reflect clinical practice.    
This is the first randomised controlled clinical trial to employ a slow-release dexamethasone 
implant in eyes with established proliferative vitreoretinopathy. We found no difference in 
anatomical retinal reattachment and PVR recurrence rates at six months, however, we did observe 
an apparent treatment effect of reduced postoperative cystoid macular edema. Further clinical 
trials are indicated to identify pharmacological agents aimed at improving anatomical and visual 
outcomes in eyes with PVR, but this study suggests that there is a greater reduction in CMO 
observed at six months in vitrectomised eyes treated with slow release dexamethasone.  
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Ozurdex in PVR Manuscript Tables 
 
 
Table 1. Non-Ocular Baseline Characteristics 
 Adjunct Group  (N=70) Control Group (N=70) 
Number of Patients (Eyes), n (%) 70 (70) 70 (70) 
Male/Female, n (%) 46 (65.7) / 24 (34.3) 40 (57) / 30 (43) 
Age in yrs, mean (SD) 60.6 (14.3) 61.6 (13.9) 
















VFQ 25, median (IQR) 
Missing, n (%) 
 
SF 36, median (IQR) 
Missing, n (%) 
 
66 (50, 77) 
1 (1.4) 
 
63 (45, 75) 
1 (1.4) 
 
65 (55, 76) 
3 (4.3) 
 
72 (52, 84) 
3 (4.3) 
VFQ 25 = visual functioning 25point questionnaire, SF 36 = social functioning 36 point 










Table 2a. Baseline Ocular Characteristics (Non-Retinal) 




Laterality (Left eye), n (%) 36 (51.4) 38 (54.3) 
Refraction (SE) median (IQR) 
Missing, n (%) 
-0.6 (-5, 0) 
9 (12.9) 
0 (-2.63, 0) 
13 (18.6) 




















2 (1, 2) 















SE = spherical equivalent, V/Gas = vitrectomy/gas, V/oil = vitrectomy/oil, V/B = 
vitrectomy/buckle, C/B = cryotherapy/buckle, OHT = Ocular hypertension, mac off 












Table 2b. Baseline Ocular Characteristics (Non-Retinal) 
 Adjunct Group (N=70) Control Group (N=70) 
ETDRS VA, median (IQR) 0 (0, 22) 0 (0, 31) 
IOP, mean (SD) 11.9 (4.9) 13.3 (5.1) 





































BCVA = Best Corrected Visual Acuity, IOP= Intraocular Pressure, AC = anterior chamber, PCIOL = posterior 













Table 3. Baseline Retinal Status 




Summed Duration of RD, median (IQR) 
Not Possible, n (%) 
28 (7, 45) 
17 (24) 
25 (11, 52) 
21 (30) 
Clock hours of RD Primary/Baseline, median (IQR) 
Not Possible, n (%) 
6 (5, 10) / 8 (6, 11) 
7 (10) / 24 (34) 
6.5 (5, 11) / 9 (6, 12) 
8 (11) / 24 (34) 

















3 (2, 4) 
4 (3, 6) 
 
 
4 (2, 6) 
4 (4, 6) 
 
RD = Retinal Detachment, PVR = Proliferative vitreoretinopathy, CP = posterior Grade C, CA = anterior Grade C 
*Measured at operation 
 
Table 4.  Operative Techniques during Study Vitrectomy 




Lensectomy, n (%) 
 
1 1 
PVD Induction, n (%) 
 
5 4 
PFCL, n (%) 
 
40 (57) 44(63) 
Retinectomy, n (%) 38(54) 39(56) 
 
PVR Membrane Peel, n (%) 42 (60) 38 (54) 
 
Segmental Buckle, n (%) 1 2 
 
Retinopexy, n (%) 
    Endolaser 







PVD = Posterior Vitreous Detachment, PFCL = Perfluorocarbon 
 
 
Table 5. Primary Outcome Result (Available ITT analysis)  





Odds Ratio(95% CI) 
Proportion of patients 
satisfying primary 
outcome measure, % 
(95% CI) 
 
49 (37, 62) 
 
46 (34, 59) 
 
0.89 (0.46, 1.74) 
 
Table 6. Secondary Outcome Measures; Visual Acuity at 6 Months 





(95% CI)  
ETDRS BCVA, mean (SD) 
- At 6 months 










1.1 (-6.3, 8.4) 
Proportion of patients achieving 
ETDRS VA ≥ 55, n (%) 
21 (30) 17 (24) - 
Sensitivity Analysis  
ETDRS BCVA, mean (SD) 
- At 6 months 













-1.2 (-8.8, 6.4) 









Table 7. Secondary Outcome Measures; Anatomical Findings at 6 months 




Overt PVR recurrence*, n (%) 40 (57) 41 (59) 
Complete retinal 
reattachment **, n (%) 
37 (53.6) 43 (62.3) 
Stable posterior retinal 
reattachment ** n (%) 
46 (66.7) 48 (69.6) 
TRD **, n (%) 15 (22) 13 (19) 
Number of procedures to 














* Between the primary study vitrectomy and 6 months, ** without silicone oil in situ 
 
Table 8. Secondary Outcome Measures; Macular Findings at 6 months 





(95% CI, p value)  
* CMO present, n (%)  29 (42.7) 45 (67.2) 2.8 (1.37 to 5.54, p = 0.004) 
  
 
** FT > 300 µm, n (%) 30 (47.6) 42 (67.7) 2.3 (1.12 to 4.78, p = 0.023)  
 
 
FT, median (IQR 
Missing, n (%) 
297 (255, 380) 
6 (9) 















Macula pucker/ERM †, 
n (%) 
40 (57) 41 (58.6) - 
ERM surgery†, n (%) 33 (47) 31 (44.3) - 
* % expressed as proportion of available cases (68 eyes in adjunct group 67 eyes control group), ** % 
expressed as proportion of available cases (63 eyes adjunct group, 62 eyes control) †  % expressed as 
proportion of n=70  
 
Supplementary Table 1. Adverse Events (AEs) 
 Adjunct Group (N=70) Control Group (N=70) 
Total number of AEs, n   285  310  
   
Number of expected AEs: n (%*)    
Cataract 0 (0)  1 (0.42) 
Raised IOP 85(39.2)  75 (31.4) 
Hypotony 27 (12.4)  31 (13) 
Sterile Hypopyon 0 (0)  1 (0.4) 
Retinal Detachment 45 (20.7)  51 (21.3) 
Uveitis 10 (4.6)  24 (10) 
Further Surgery 41 (18.9)  51 (21.3) 
Glaucoma 3 (1.4) 2 (0.8) 
Headache 5 (2.3) 1 (0.4) 
Migraine 1 (0.5) 2 (0.8) 
Vitreous Opacities 0 (0) 0 (0) 
Tractional Maculopathy 0 (0) 0 (0) 
Number of unexpected AEs: n (%)   
Systemic Illness 15 (22) 18 (25.4) 
Ocular Vascular Occlusion 3 (4.4) 3 (4) 
Raised Blood Pressure 6 (8.8) 6 (8.5) 
Iris Bombe 6 (8.8) 6 (8.5) 
Fellow Eye RD Surgery*, n (%) 





Other (Ocular), n (%) 10 (14.7)  17 (23.9) 
Other (Non-Ocular), n (%) 26 (38.2) 20 (28.2) 
(Percentages calculated in relation to total number of Expected and unexpected AEs in each group) 
Supplementary Table 2 Serious Adverse Events (SAEs) 
 Adjunct Group (N=70) Control Group (N=70) 
Total number of patients with at 
least one SAE, n  
7  6  
Total number SAEs 
 
 10  7  
Number of unexpected SAEs: n (%)   
Systemic Illness, n (%) 9 (90) 4 (57) 
Other (Ocular), n (%) 1(10) 0 (0) 
Other (Non-Ocular), n (%) 0 (0) 3 (42.9) 





Supplementary Table 3. Quality of Life Outcome Measures at 6 months 
 Adjunct Group (N=69) Control Group 
(N=69) 
Effect Estimate 
(95% CI, p value)  
Score for: 
VFQ 25, mean (SD) 
- At 6 months 
- Change from baseline at 
6 months* 
Missing (change), n (%) 
 
SF 36, mean (SD) 
- At 6 months 
- Change from baseline at 
6 months* 


































3.1 (-3.1, 9.3) 
 
Ozurdex in PVR Study 
Figure 1. Ozurdex in PVR Consort Diagram 
 
          
Assessed for eligibility (n=192) 
- Did not meet inclusion criteria n=29   
- Eligible but not enrolled n = 20 
- Enrolled but not randomised n=3 




¨ Excluded from analysis (n=69 ) 
Primary Outcome data available (n=69) 
Outcome data not available (n=1)  
  
Allocated to intervention A (n=70) 
¨ Received allocated intervention (n=68) 
¨ Did not receive allocated intervention  (n=2 
1X lensectomy/1 X gas used) 
  
Outcome data available (n=69) 
Outcome data not available (n=1)  
(lost to follow up after 3 months) 
Allocated to intervention B (n=70) 
¨ Received allocated intervention (n=70) 
¨ Did not receive allocated intervention (n=0) 
  
Analysed (n=69) 
¨ Excluded from analysis (n=1) 
  
Allocation 
Analysis 
Follow-Up 
Randomized (n=140) 
Enrollment 
